Table 2.
Effect of niacin on mineral metabolism parameters in CKD participants in the AIM-HIGH Trial (intent to treat analysis)
| Variables | Placebo | Niacin | P Value |
|---|---|---|---|
| Phosphate, mg/dl | |||
| Baseline, n=351, mean±SD | 3.4±0.6 | 3.4±0.6 | 0.85 |
| Year 1, n=291, mean±SD | 3.4±0.6 | 3.4±0.6 | 0.76 |
| Year 3, n=139, mean±SD | 3.6±0.5 | 3.3±0.5 | 0.003 |
| Difference in slopes (95% CI) | −0.08 (−0.13 to −0.02) | <0.01 | |
| Intact FGF23, pg/ml | |||
| Baseline, n=352, median (IQR) | 74 (60–97) | 72 (54–101) | 0.75 |
| Year 1, n=297, median (IQR) | 80 (60–102) | 73 (60–102) | 0.09 |
| Year 3, n=140, median (IQR) | 71 (54–94) | 75 (57–102) | 0.87 |
| Difference in slopes (95% CI) | −0.47 (−5.49 to 4.53) | 0.86 | |
| Calcium, mg/dl | |||
| Baseline, n=344, mean±SD | 9.5±0.6 | 9.7±0.5 | 0.03 |
| Year 1, n=289, mean±SD | 9.6±0.5 | 9.6±0.6 | 0.16 |
| Year 3, n=135, mean±SD | 9.6±0.5 | 9.7±0.6 | 0.77 |
| Difference in slopes (95% CI) | −0.03 (−0.08 to 0.03) | 0.31 | |
| Intact PTH, pg/ml | |||
| Baseline, n=349, median (IQR) | 53 (38–76) | 51 (36–71) | 0.57 |
| Year 1, n=295, median (IQR) | 54 (34–75) | 44 (29–65) | 0.003 |
| Year 3, n=140, median (IQR) | 51 (34–79) | 45 (36–67) | 0.87 |
| Difference in slopes (95% CI) | −2.11 (−4.94 to 0.71) | 0.14 | |
| 25-Hydroxyvitamin D, ng/ml | |||
| Baseline, n=339, mean±SD | 25±9 | 25±10 | 0.67 |
| Year 1, n=280, mean±SD | 26±9 | 26±10 | 0.89 |
| Year 3, n=135, mean±SD | 28±10 | 26±11 | 0.29 |
| Difference in slopes (95% CI) | −0.48 (−1.32 to 0.35) | 0.26 | |
| 1,25-Dihydroxyvitamin D, ng/ml | |||
| Baseline, n=339, mean±SD | 32±11 | 32±11 | 0.32 |
| Year 1, n=280, mean±SD | 31±11 | 31±10 | 0.78 |
| Year 3, n=135, mean±SD | 33±12 | 32±13 | 0.59 |
| Difference in slopes (95% CI) | −0.17 (−1.33 to 0.98) | 0.77 | |
| 24,25-Dihydroxyvitamin D, ng/ml | |||
| Baseline, n=339, mean±SD | 2.8±1.7 | 2.7±1.6 | 0.57 |
| Year 1, n=280, mean±SD | 2.9±1.6 | 2.8±1.6 | 0.94 |
| Year 3, n=135, mean±SD | 2.9±1.0 | 2.8±1.0 | 0.51 |
| Difference in slopes (95% CI) | <0.01 (−0.10 to 0.11) | 0.95 | |
AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health; 95% CI, 95% confidence interval; FGF23, fibroblast growth factor 23; IQR, interquartile range; PTH, parathyroid hormone.